I recently had the opportunity to interview Dan Rose, CEO of the French-based medtech company LimFlow. Founded in 2012, LimFlow transformed the peripheral vasculature space by providing a lifesaving option for end-stage critical limb-threatening ischemia (CLTI) patients facing amputation. LimFlow is designed to restore blood flow to the ischemic foot via deep vein arterialization, thereby preventing major amputation, resolving pain, and promoting wound healing. 

Prior to assuming the role of CEO at LimFlow in August 2016, Dan had more than 16 years of leadership experience in the medical device and venture capital/startup sectors. Most recently, he was VP and General Manager EMEA for Direct Flow Medical, and VP of Commercial Operations and a Member of the Board at Sequana Medical, a Swiss medical device company. 

Norbert Juist, an executive recruiter who specializes in medical device sales and marketing, also joined me for this interview with Dan Rose. Norbert brings a unique perspective to this discussion, having worked as a sales rep and consultant in medtech for nearly 20 years prior to transitioning to executive recruiting.

Here are a few of the topics we discuss in this episode:

• How LimFlow used a concept that’s been in existence since 1912 and transformed it into a modern therapy that multidisciplinary clinicians can reproduce.
• How Med Start played an instrumental role in the launch and ultimate success of LimFlow.
• Why it’s essential to find a physician champion willing to invest time and energy in your tech.
• Overcoming the challenges presented by an ever-evolving MDR landscape, both in the EU and US.
• Key factors you can’t ignore if you want to succeed as a first-time CEO.
• Why investing in independent market research is well worth the cost.
• Why the FDA Breakthrough Devices Program has been a game changer in the US.

See more...